Skip to main content
. 2024 Aug 28;12(17):1718. doi: 10.3390/healthcare12171718

Table 1.

This is a schematic summarization of our cohort. It shows data of our cohort evaluated as a whole and sorted per histological grading. Statistically significant differences between high-grade and low-grade populations are reported in column p on the right.

Low-Grade
(n = 20)		 High-Grade
(n = 10)		 Total
Population
(n = 30)		 p
(<0.05)
Number 20 10 30 -
Mean Age
(min–max)		 45.5
(17–71)		 56.7
(25–77)		 49.2
(17–77)		 -
Gender
Female
Male
11
9
2
8
13
17		 -
Average
Diagnostic Interval
(min–max)		 7.7
(1–16)		 7.5
(1–60)		 7.6
(1–60)
Localization
Anterior Compartment
Medial Compartment
Posterior Compartment
7
6
7
5
2
3
12
8
10		 -
Mean Size
(min–max)		 11.2 cm
(5–18)		 13.2 cm
(5–23)		 11.9 cm
(5–23)		 -
Pre-Op Swelling
(percentage)		 20
(100%)		 10
(100%)		 30
(100%)		 -
Pre-Op Pain
(percentage)		 2
(10%)		 0 2
(7%)		 -
Mean Pre-Op
MSTS Score
(min–max)		 26.0
(15–29)		 25.2
(15–29)		 25.8
(15–29)		 -
Pre-Op
Radiotherapy
(percentage)		 0 8
(80%)		 9
(27%)		 -
Margins
Wide
Marginal
16
4
8
2
24
6		 -
Intra-Op
Complications 		0 0 0 -
Post-Op
Complications
(percentage)
Seroma
Infection
Dehiscence
Dysesthesia 		4
(20%)
1
1
1
1		 2
(20%)
1
1
0
0		 6
(20%)
2
2
1
1		 -
Post-Op
Radiotherapy
(percentage)		 3
(15%)		 0 3
(10%)		 -
Local
Recurrences
(percentage)		 4
(20%)		 1
(10%)		 5
(15%)		 FISHER’S EXACT TEST:
Contingency between
low grade and local
recurrence (p = 0.041)
Metastases
(percentage)		 0 3
(33%)		 3
(10%)		 FISHER’S EXACT TEST:
Contingency between
high-grade lesions and metastases (p = 0.031)
Oncological
Outcomes
CDF (percentage)
DOC (percentage)
NED (percentage)
AWD (percentage)
DOD (percentage)

15 (75%)
0
3 (15%)
1 (5%)
1 (5%)

5 (50%)
1 (10%)
2 (20%)
1 (10%)
1 (10%)

21 (70%)
1 (3%)
5 (17%)
2 (7%)
1 (3%)		 -
Mean Post-Op
MSTS Score
(min–max)		 26.7
(15–30)		 27.6
(25–30)		 27.0
(15–30)		 -
Follow-Up
(min–max)		 60.4 months
(21–89)		 53.5 months
(20–72)		 58.1 months
(20–89)		 -